Skip to content

Adaptive Enhancement and Clinical Efficacy Evaluation of Digital Therapies for Cognitive Rehabilitation in Schizophrenia: Part II

Adaptive Enhancement and Clinical Efficacy Evaluation of Digital Therapies for Cognitive Rehabilitation in Schizophrenia: Part II

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500102208
Enrollment
Unknown
Registered
2025-05-12
Start date
2025-05-12
Completion date
Unknown
Last updated
2025-05-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia

Interventions

Intervention Group:Digital Cognitive Training
Control Group:computer games

Sponsors

Peking University Sixth Hospital (Institute of Mental Health)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 50 Years

Inclusion criteria

Inclusion criteria: 1. Diagnosis of schizophrenia according to DSM-5 criteria (clinical interview/medical record documentation). 2. Stable condition for >= 3 months, without the need for increased psychiatric rehabilitation care due to worsening of schizophrenia. 3. Age 18-50 years. 4. Ability to understand and read Chinese, comprehend the testing procedures, and use a tablet for cognitive training. 5. Ability to understand the informed consent content and study procedures, and to sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Presence of other diseases that may affect cognitive function, including but not limited to: intellectual disability, dementia, or head trauma with loss of consciousness exceeding 1 hour. 2. Presence of severe motor incoordination (including extrapyramidal symptoms caused by antipsychotic medications). 3. Presence of suicide risk (suicidal behavior within the past year, suicidal ideation or attempts within the past 3 months). 4. Received MECT (modified electroconvulsive therapy) within the past six months. 5. Recently received or are currently receiving other treatments that may affect cognitive function (at the discretion of the investigator): including clozapine, ketamine, stimulants, potent or moderate CYP3A4 inhibitors/inducers; antiepileptic drugs, tricyclic antidepressants, traditional Chinese medicine/non-Western medicine that may affect cognition, dietary supplements and herbs, rTMS (repetitive transcranial magnetic stimulation), cognitive training, etc.

Design outcomes

Primary

MeasureTime frame
Chinese Brief Cognitive Test;

Secondary

MeasureTime frame
Personal and Social Performance Scale;Schizophrenia Cognition Rating Scale;

Countries

China

Contacts

Public ContactChuan Shi

Peking University Sixth Hospital(Institute of Mental Health)

shichuan@bjmu.edu.cn+86 136 1117 4272

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026